The prognostic value of polycomb group protein B-cell-specific moloney murine leukemia virus insertion site 1 in stage II colon cancer patients

The aim of this study was to investigate the prognostic value of B‐cell‐specific moloney murine leukemia virus insertion site 1 (BMI1) protein expression in primary tumors of stage II colon cancer patients. BMI1 protein expression was assessed by immunohistochemistry in a retrospective patient cohor...

Full description

Saved in:
Bibliographic Details
Published in:APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2016-07, Vol.124 (7), p.541-546
Main Authors: Espersen, Maiken L. M., Linnemann, Dorte, Christensen, Ib J., Alamili, Mahdi, Troelsen, Jesper T., Høgdall, Estrid
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
B-cell-specific moloney murine leukemia virus insertion site 1
biomarkers
Biomarkers, Tumor - analysis
colon cancer
Colonic Neoplasms - diagnosis
Colonic Neoplasms - pathology
Colorectal cancer
Female
Humans
Immunohistochemistry
Leukemia
Male
Middle Aged
Moloney murine leukemia virus
Polycomb Repressive Complex 1 - analysis
Prognosis
Protein expression
Proteins
Recurrence
Retrospective Studies
Survival Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate the prognostic value of B‐cell‐specific moloney murine leukemia virus insertion site 1 (BMI1) protein expression in primary tumors of stage II colon cancer patients. BMI1 protein expression was assessed by immunohistochemistry in a retrospective patient cohort consisting of 144 stage II colon cancer patients. BMI1 expression at the invasive front of the primary tumors correlated with mismatch repair status of the tumors. Furthermore, BMI1 expression at the luminal surface correlated with T‐stage, tumor location, and the histological subtypes of the tumors. In a univariate Cox proportional hazard analysis, no statistical significant association between risk of relapse and BMI1 protein expression at the invasive front (HR: 1.12; 95% CI 0.78–1.60; p = 0.53) or at the luminal surface of the tumor (HR: 1.06; 95% CI 0.75–1.48; p = 0.70) was found. Likewise, there was no association between 5‐year overall survival and BMI1 expression at the invasive front (HR: 1.12; 95% CI 0.80–1.56; p = 0.46) or at the luminal surface of the tumor (HR: 1.16; 95% CI 0.86–1.60; p = 0.33). In conclusion, BMI1 expression in primary tumors of stage II colon cancer patients could not predict relapse or overall survival of the patients, thus having a limited prognostic value in stage II colon cancer patients.
ISSN:0903-4641
1600-0463
DOI:10.1111/apm.12539